drugset / Trial / NCT01033344
Cat-PAD Exposure Chamber Study
Phase 2
Completed
210 enrolled
Circassia Limited
Adiga Life Sciences, Inc. · collabCetero Research, San Antonio · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy. This study will look at the efficacy, safety and tolerability of two doses of Cat-PAD in cat allergic subjects following challenge to cat allergen in an EEC.
Timeline
- Start
- 2010-01
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cat-PAD | Peptide | — | Other |
Indications
No indication recorded.